Prevalence of aflatoxin induced p53 mutation at codon 249 (r249s) in hepatocellular carcinoma patients with and without Hepatitis B surface antigen (HBsAg)

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7675-7679

  Chittmittrapap, Salyavit ^a   Chieochansin, Thaweesak ^a   Chaiteerakij, Roongruedee ^a   Treeprasertsuk, Sombat ^a   Klaikaew, Naruemon ^a   Tangkijvanich, Pisit ^a   Komolmit, Piyawat ^a   Poovorawan, Yong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

249ser; Aflatoxin B1; HBsAg; Hepatocellular carcinoma; p53 mutation; R249S

Indexed keywords

AFLATOXIN; DNA; HEPATITIS B SURFACE ANTIGEN; POISON; PROTEIN P53; TP53 PROTEIN, HUMAN; VIRUS DNA;

ARTICLE; BLOOD; CANCER STAGING; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROLOGY; VIROLOGY;

AFLATOXINS; CARCINOMA, HEPATOCELLULAR; DNA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POISONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; PROGNOSIS; SEROLOGIC TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893366983     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7675     Document Type: Article

References (40)

1. Behn M, Qun S, Pankow W, Havemann K, Schuermann M (1998). Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique. Clin Cancer Res, 4, 361-71.
2. Besaratinia A, Kim SI, Hainaut P, Pfeifer GP (2009). In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterol, 137, 1127-37.
3. Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-31.
4. Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
5. Buetow KH, Sheffield VC, Zhu M, et al (1992). Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA, 89, 9622-6.
6. Cuny M, Kramar A, Courjal F, et al (2000). Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res, 60, 1077-83.
7. Dupont WD, Plummer WD (1990). Power and sample size calculations. A review and computer program. Control Clin Trials, 11, 116-28.
8. El-Kafrawy SA, Abdel-Hamid M, El-Daly M, et al (2005). P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health, 208, 263-70.
9. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol, 132, 2557-76.
10. Gouas DA, Shi H, Hautefeuille AH, et al (2010). Effects of the TP53 p. R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis, 31, 1475-82.
11. Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG, (2013). Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol Lett, 5, 1087-92.
12. Hoque A, Patt YZ, Yoffe B, et al (1999). Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States? Nutr Cancer, 35, 27-33.
13. Hsu IC, Metcalf RA, Sun T, et al (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-8.
14. Jiang W, Wang XW, Unger T, et al (2010). Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer, 127, 1011-20.
15. Khlangwiset P, Wu F (2010). Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease. Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 27, 998-1014.
16. Kirk GD, Lesi OA, Mendy M, et al (2005). 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24, 5858-67.
17. Liu Y, Wu F (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118, 818-24.
18. Nogueira JA, Ono-Nita SK, Nita ME, et al (2009). 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC cancer, 9, 204.
19. O'Brien A, Williams R (2008). Nutrition in end-stage liver disease: principles and practice. Gastroenterol, 134, 1729-40.
20. Ortiz-Cuaran S, Villar S, Gouas D, et al (2013). Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a casecontrol study from Thailand. Cancer Lett, 331, 46-51.
21. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al (2012). Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. Hum Vaccin Immunother, 8, 896-904.
22. Qian GS, Kuang SY, He X, Groopman JD, Jackson PE (2002). Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP. Cancer Epidemiol Biomarkers Prev, 11, 1126-9.
23. Qu JH, Zhu MH, Lin J, et al (2005). Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721. World J Gastroenterol, 11, 6212-5.
24. Ross RK, Yuan JM, Yu MC, et al (1992). Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-6.
25. Smela ME, Hamm ML, Henderson PT, et al (2002). The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci USA, 99, 6655-60.
26. Soini Y, Chia SC, Bennett WP, et al (1996). An aflatoxinassociated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis, 17, 1007-12.
27. Sripathomswat N, Thasnakorn P (1981). Survey of aflatoxinproducing fungi in certain fermented foods and beverages in Thailand. Mycopathologia, 73, 83-8.
28. Srivatanakul P, Sriplung H, Deerasamee S, (2004). Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev, 5, 118-25.
29. Stern MC, Umbach DM, Yu MC, et al (2001). Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, people's republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev, 10, 617-25.
30. Szymanska K, Lesi OA, Kirk GD, et al (2004). Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer, 1103, 374-9.
31. Thongbai C, Sa-nguanmoo P, Kranokpiruk P, et al (2013). Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand. Asian Pac J Cancer Prev, 14, 3555-9.
32. Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al (2012). Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis, PloS One, 7, 37707.
33. Volkmann M, Hofmann WJ, Muller M, et al (1994). p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene, 9, 195-204.
34. Waenlor W, Wiwanitkit V (2003). Aflatoxin contamination of food and food products in Thailand: an overview. Southeast Asian J Trop Med Public Health, 34, 184-90.
35. Wang LY, Hatch M, Chen CJ, et al (1996). Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer, 67, 620-5.
36. Wichajarn K, Kosalaraksa P, Wiangnon S (2008). Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev, 9, 507-9.
37. Williams JH, Phillips TD, Jolly PE, et al (2004). Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr, 80, 1106-22.
38. Wu HC, Wang Q, Yang HI, et al (2009). Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev, 18, 846-53.
39. Yang M, Zhou H, Kong RY, et al (1997). Mutations at codon 249 of p53 gene in human hepatocellular carcinomas from Tongan, China. Mutat Res, 381, 25-9.
40. Yoo KY (2010). Cancer prevention in the Asia Pacific region. Asian Pac J Cancer Prev, 11, 839-844.